Mauro Schechter

Summary

Affiliation: Rio de Janeiro
Country: Brazil

Publications

  1. ncbi request reprint Discordant immunological and virological responses to antiretroviral therapy
    Mauro Schechter
    Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro Av Brigadeiro Trompowski s n, Ilha do Fundao, Rio de Janeiro 21941 590, Brazil
    J Antimicrob Chemother 58:506-10. 2006
  2. pmc Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings
    Alexandra Calmy
    HIV Unit, Geneva University Hospital, Geneva, Switzerland
    BMC Infect Dis 12:147. 2012
  3. ncbi request reprint Identification of a high-risk heterosexual population for HIV prevention trials in Rio de Janeiro, Brazil. Projeto Praço Onze Study Group
    M Schechter
    Infectious Diseases Service, Hospital Universitario Clementino Fraga Filho, Department of Preventive Medicine, Universidade Federal do Rio de Janeiro, Brazil
    J Acquir Immune Defic Syndr 24:175-7. 2000
  4. ncbi request reprint Monotherapy with lopinavir/ritonavir
    Mauro Schechter
    Projeto Praça Onze, Universidade Federal do Rio de Janeiro, Brazil
    Expert Opin Investig Drugs 16:735-41. 2007
  5. ncbi request reprint Treatment at scale in Brazil: a physician's perspective
    Mauro Schechter
    Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rua Professor Rodolpho Paulo Rocco no, 255, Ilha do Fundao, CEP 21941 590 Rio de Janeiro, SP, Brazil
    AIDS 21:S31-5. 2007
  6. ncbi request reprint Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV
    Mauro Schechter
    Infectious Diseases Service, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    J Acquir Immune Defic Syndr 35:519-25. 2004
  7. doi request reprint Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study)
    Estevão P Nunes
    Projeto Praça Onze, Hospital Escola Sao Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    HIV Clin Trials 10:368-74. 2009
  8. ncbi request reprint Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil
    Tania R C Vergara
    Infectious Diseases Service, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Brazil
    Ther Drug Monit 28:175-9. 2006
  9. ncbi request reprint HIV vaccine evaluation center in Rio de Janeiro, Brazil
    Mauro Schechter
    Universidade Federal do Rio de Janeiro, Av Brig Trompowski, CEP 21941 590, Rio de Janeiro, Brazil
    Vaccine 20:1909-11. 2002
  10. pmc Estimating the extent of underreporting of mortality among HIV-infected individuals in Rio de Janeiro, Brazil
    Antonio G Pacheco
    FIOCRUZ, Rio de Janeiro, Brazil
    AIDS Res Hum Retroviruses 27:25-8. 2011

Research Grants

Detail Information

Publications47

  1. ncbi request reprint Discordant immunological and virological responses to antiretroviral therapy
    Mauro Schechter
    Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro Av Brigadeiro Trompowski s n, Ilha do Fundao, Rio de Janeiro 21941 590, Brazil
    J Antimicrob Chemother 58:506-10. 2006
    ....
  2. pmc Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings
    Alexandra Calmy
    HIV Unit, Geneva University Hospital, Geneva, Switzerland
    BMC Infect Dis 12:147. 2012
    ..We assessed the impact of on-going HIV-RNA replication on CD4 cell count slopes in patients treated with a first-line combination ART...
  3. ncbi request reprint Identification of a high-risk heterosexual population for HIV prevention trials in Rio de Janeiro, Brazil. Projeto Praço Onze Study Group
    M Schechter
    Infectious Diseases Service, Hospital Universitario Clementino Fraga Filho, Department of Preventive Medicine, Universidade Federal do Rio de Janeiro, Brazil
    J Acquir Immune Defic Syndr 24:175-7. 2000
    ..This study demonstrates the usefulness of the newly described S/LS assay, which allows one to estimate HIV incidence from single serum specimens...
  4. ncbi request reprint Monotherapy with lopinavir/ritonavir
    Mauro Schechter
    Projeto Praça Onze, Universidade Federal do Rio de Janeiro, Brazil
    Expert Opin Investig Drugs 16:735-41. 2007
    ....
  5. ncbi request reprint Treatment at scale in Brazil: a physician's perspective
    Mauro Schechter
    Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rua Professor Rodolpho Paulo Rocco no, 255, Ilha do Fundao, CEP 21941 590 Rio de Janeiro, SP, Brazil
    AIDS 21:S31-5. 2007
    ..The Brazilian experience also shows that operational research should be an integral part of programmes of access to treatment, if their long-term sustainability is to be ensured...
  6. ncbi request reprint Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV
    Mauro Schechter
    Infectious Diseases Service, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    J Acquir Immune Defic Syndr 35:519-25. 2004
    ..Little is known about the behavioral impact, acceptability, and incidence of HIV infection in persons with easy access to post-sexual exposure prophylaxis (PEP) to prevent HIV...
  7. doi request reprint Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study)
    Estevão P Nunes
    Projeto Praça Onze, Hospital Escola Sao Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    HIV Clin Trials 10:368-74. 2009
    ..Long-term adverse events and expenses associated with HAART have led to an interest in simplified therapy. Lopinavir/ritonavir monotherapy is attractive due to its potency and high genetic barrier...
  8. ncbi request reprint Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil
    Tania R C Vergara
    Infectious Diseases Service, Hospital Universitario Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Brazil
    Ther Drug Monit 28:175-9. 2006
    ..HIV-1 viral load was detectable in the semen of 2 and in the blood of 6 of 16 patients. These results may have implications for drug-resistant HIV-1 evolution and transmission...
  9. ncbi request reprint HIV vaccine evaluation center in Rio de Janeiro, Brazil
    Mauro Schechter
    Universidade Federal do Rio de Janeiro, Av Brig Trompowski, CEP 21941 590, Rio de Janeiro, Brazil
    Vaccine 20:1909-11. 2002
    ..A phase 3 HIV vaccine trial is planned to begin in the next 18-24 months...
  10. pmc Estimating the extent of underreporting of mortality among HIV-infected individuals in Rio de Janeiro, Brazil
    Antonio G Pacheco
    FIOCRUZ, Rio de Janeiro, Brazil
    AIDS Res Hum Retroviruses 27:25-8. 2011
    ....
  11. ncbi request reprint Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil
    Cristina B Hofer
    Infectious Diseases Service, Hospital Universitario Clementino Fraga Filho, Department of Preventive Medicine, Universidade Federal do Rio de Janeiro, Brazil
    J Acquir Immune Defic Syndr 36:967-71. 2004
    ..Brazil provides antiretroviral therapy (ART) to HIV-infected persons free of charge. The objective of this study was to investigate factors associated with ART failure in patients receiving free ART in public clinics in Brazil...
  12. ncbi request reprint Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy
    Marcelo Vianna Vettore
    Infectious Diseases Service, Department of Preventive Medicine, Hospital Universitario Clementino Fraga Filho, School of Medicine, Universidade Federal do Rio de Janeiro, Brazil
    J Infect 52:290-3. 2006
    ..Cervicovaginal secretions represent the primary vehicle in mother to infant and sexual HIV-1 transmission. Understanding the viral dynamics in this compartment is important to improve interventions to decrease HIV transmission...
  13. pmc Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean
    Suely H Tuboi
    Projeto Praça Onze, Hospital Universitario Clementino Fraga Filho and Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    J Acquir Immune Defic Syndr 51:615-23. 2009
    ..Although nearly 2 million people live with HIV in Latin America and the Caribbean, mortality rates after initiation of highly active antiretroviral therapy (HAART) have not been well described...
  14. ncbi request reprint Risk-based assessment does not distinguish between recent and chronic HIV-1 infection in Rio de Janeiro, Brazil
    Mônica Merçon
    Projeto Praça Onze, Hospital Escola Sao Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
    Braz J Infect Dis 13:272-5. 2009
    ..Steady relationships and serosorting may be playing a key role in maintaining the HIV epidemics in Brazil...
  15. pmc Increase in non-AIDS related conditions as causes of death among HIV-infected individuals in the HAART era in Brazil
    Antonio G Pacheco
    Department of Epidemiology and Quantitative Methods in Health, National School of Public Health Scientific Computing Program, Oswaldo Cruz Foundation FIOCRUZ, Rio de Janeiro, Brazil
    PLoS ONE 3:e1531. 2008
    ....
  16. ncbi request reprint Adherence to antiretroviral therapy and persistence of HIV RNA in semen
    Paulo F Barroso
    Infectious Diseases Sevice, Department of Preventive Medicine, Hospital Universitario Clementino Fraga Filho, School of Medicine, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
    J Acquir Immune Defic Syndr 32:435-40. 2003
    ..Although antiretroviral therapy (ART) reduces HIV seminal shedding, little is known about the relationship between adherence to ART and HIV suppression in semen...
  17. ncbi request reprint Assessing sexually transmitted infections in a cohort of women living with HIV/AIDS, in Rio de Janeiro, Brazil
    Beatriz Grinsztejn
    Evandro Chagas Clinical Research Institute FIOCRUZ, Av Brasil, 4365 Manguinhos, Rio de Janeiro, Brazil
    Int J STD AIDS 17:473-8. 2006
    ..Reproductive counselling should be a part of this approach...
  18. ncbi request reprint Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy
    Guilherme Santoro-Lopes
    Infectious Diseases Clinic, Department of Preventive Medicine, Hospital Universitario Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
    Clin Infect Dis 34:543-6. 2002
    ..The use of highly active antiretroviral therapy in regions with a high prevalence of coinfection with HIV and Mycobacterium tuberculosis may contribute a lower incidence of tuberculosis...
  19. pmc Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts
    Mauro Schechter
    Infectious Diseases Service, Hospital Universitario Clementino Fraga Filho, Rio de Janeiro, Brazil
    Am J Respir Crit Care Med 173:922-6. 2006
    ..Treatment of latent tuberculosis (TB) infection with weekly rifapentine and isoniazid is a potentially effective alternative to current therapies...
  20. pmc Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries
    Martin W G Brinkhof
    Institute of Social and Preventive Medicine ISPM, University of Berne, Finkenhubelweg 11, CH 3012 Bern, Switzerland
    Clin Infect Dis 45:1518-21. 2007
    ..48 (95% confidence interval, 0.36-0.64) in low-income countries and 0.36 (95% confidence interval, 0.26-0.50) in high-income countries. A low CD4 cell count at the start of therapy was the most important risk factor in both settings...
  21. ncbi request reprint Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme
    Catherine C McGowan
    Vanderbilt University School of Medicine, Nashville, TN, USA
    Int J Epidemiol 36:969-76. 2007
  22. ncbi request reprint Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120
    Farley Cleghorn
    Center for HIV AIDS, Constella Futures, Washington, DC, USA
    J Acquir Immune Defic Syndr 46:222-30. 2007
    ..vCP1452 was administered alone or with a heterologous boost of MN rgp120 glycoprotein. The trial was pivotal in deciding whether these vaccines advanced to phase 3 efficacy trials...
  23. doi request reprint Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration
    Paula Braitstein
    Department of Medicine, Indiana University, Indianapolis, Indiana, USA
    J Womens Health (Larchmt) 17:47-55. 2008
    ....
  24. doi request reprint Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs
    Carlo Federico Perno
    Department of Experimental Medicine and Biochimical Science, University of Rome Tor Vergata, Rome, Italy
    J Med Virol 80:565-76. 2008
    ....
  25. pmc Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America
    Olivia Keiser
    Institute of Social and Preventive Medicine ISPM, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland
    Trop Med Int Health 13:870-9. 2008
    ..To describe temporal trends in baseline clinical characteristics, initial treatment regimens and monitoring of patients starting antiretroviral therapy (ART) in resource-limited settings...
  26. doi request reprint Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection
    Graeme Moyle
    HIV Research Chelsea and Westminster Hospital, London, United Kingdom
    AIDS Patient Care STDS 22:459-71. 2008
    ....
  27. doi request reprint Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection
    David A Cooper
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney
    N Engl J Med 359:355-65. 2008
    ....
  28. pmc Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
    Martin W G Brinkhof
    Institute of Social and Preventive Medicine, Bern, Switzerland
    Bull World Health Organ 86:559-67. 2008
    ..To analyse the early loss of patients to antiretroviral therapy (ART) programmes in resource-limited settings...
  29. doi request reprint Raltegravir with optimized background therapy for resistant HIV-1 infection
    Roy T Steigbigel
    State University of New York at Stony Brook, Stony Brook, USA
    N Engl J Med 359:339-54. 2008
    ..Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs...
  30. ncbi request reprint Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil
    Suely H Tuboi
    Infectious Diseases Epidemiology Research Unit, Graduate School of Public Health and School of Medicine, University of Pittsburgh, PA, USA
    J Acquir Immune Defic Syndr 40:324-8. 2005
    ..To assess predictors of virologic response 6 months after initiation of highly active antiretroviral therapy (HAART) in a cohort of HIV-infected patients in Brazil...
  31. ncbi request reprint Identification of a high-risk heterosexual cohort for HIV vaccine efficacy trials in Rio de Janeiro, Brazil, using a sensitive/less-sensitive assay: an update
    Paulo Feijó Barroso
    J Acquir Immune Defic Syndr 36:880-1. 2004
  32. ncbi request reprint Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
    JAMA 292:251-65. 2004
    ..Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection...
  33. ncbi request reprint Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014)
    Asda Vibhagool
    Medicine Department, Faculty of Medicine, Ramathibodi Hospital Mahidol University, Bangkok, Thailand
    Curr Med Res Opin 20:1103-14. 2004
    ..a regimen containing the protease inhibitor indinavir (IDV) 800 mg three times daily plus COM twice daily (IDV/COM) in antiretroviral-naïve, HIV-infected patients...
  34. ncbi request reprint Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine
    Pedro Cahn
    Fundacion Huesped, Buenos Aires, Argentina
    Curr Med Res Opin 20:1115-23. 2004
    ....
  35. ncbi request reprint Therapy for early HIV infection: how far back should the pendulum swing?
    Mauro Schechter
    J Infect Dis 190:1043-5. 2004
  36. pmc Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1
    Frank van Leth
    International Antiviral Therapy Evaluation Center, Division of Infectious Diseases, Tropical Medicine, and AIDS, Department of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands
    PLoS Med 1:e19. 2004
    ..We analysed whether lipid changes differed between the two most commonly used NNRTIs, nevirapine (NVP) and efavirenz (EFV)...
  37. ncbi request reprint Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Hopital Bichat Claude Bernard, Department of Infectious Diseases, 46 rue Henri Huchard, Paris, Cedex 18 France 75877
    JAMA 288:222-35. 2002
    ..These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care...
  38. ncbi request reprint High prevalence of sexually transmitted diseases in young women seeking HIV testing in Rio de Janeiro, Brazil
    Robert L Cook
    Division of General Internal Medicine, Graduate School of Public Health, University of Pittsburgh, Pennsylvania 15213, USA
    Sex Transm Dis 31:67-72. 2004
    ..Few data are available on the prevalence of and risk factors for sexually transmitted diseases (STDs) other than HIV in Brazil...
  39. ncbi request reprint Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts
    Francois Dabis
    INSERM U 593, ISPED, Universite Victor Segalen, Bordeaux Cedex, France
    Int J Epidemiol 34:979-86. 2005
  40. ncbi request reprint Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration
    Suely H Tuboi
    Infectious Diseases Epidemiology Research Unit, Graduate School of Public Health and School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    J Acquir Immune Defic Syndr 45:52-9. 2007
    ..To assess the frequency of and risk factors for discordant responses at 6 months on highly active antiretroviral therapy (HAART) in previously treatment-naive HIV patients from resource-limited countries...
  41. ncbi request reprint Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries
    Paula Braitstein
    Lancet 367:817-24. 2006
    ..We compared baseline characteristics and outcomes during the first year of HAART between HIV-1-infected patients in low-income and high-income settings...
  42. ncbi request reprint Viral load and CD4 count dynamics after HIV-1 seroconversion in homosexual and bisexual men in Rio de Janeiro, Brazil
    Gaston Djomand
    HIV Vaccine Trials Network, Seattle, WA, USA
    J Acquir Immune Defic Syndr 43:401-4. 2006
    ..Reliable predictors of HIV disease progression are scarce in developing countries, where most HIV infections occur. We describe early virologic and immunologic events among men who have sex with men in Rio de Janeiro, Brazil...
  43. ncbi request reprint Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    JAMA 296:827-43. 2006
    ..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field...
  44. doi request reprint The use of supplementary techniques to increase recall of sex partners in a network-based research study in Rio de Janeiro, Brazil
    André R S Périssé
    Institute of Human Virology, University of Maryland, Baltimore, MD, USA
    Sex Transm Dis 35:674-8. 2008
    ..To evaluate supplementary cueing as a technique to increase recall of sex partners in the year before the interview...
  45. ncbi request reprint Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon
    Swati B Gupta
    Merck and Co, Inc, Whitehouse Station, NJ, USA
    J Acquir Immune Defic Syndr 42:135-9. 2006
    ..Substantial cross-clade cell-mediated immune responses in Botswana and Cameroon confirm previous findings in a larger, more genetically diverse collection of HIV-1 samples...
  46. ncbi request reprint Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents
    Paul M Coplan
    Merck Research Laboratories, West Point, Pennsylvania, USA
    J Infect Dis 191:1427-34. 2005
    ..Therefore, we quantified the cross-clade reactivity, among unvaccinated individuals, of anti-HIV-1 T cell responses to the infecting HIV-1 clade relative to other major circulating clades...
  47. ncbi request reprint Antiretroviral therapy in resource-poor settings: scaling up inequalities?
    Matthias Egger
    Int J Epidemiol 34:509-12. 2005

Research Grants2

  1. Universidade Federal do Rio de Janeiro Clinical Trials Unit
    Mauro Schechter; Fiscal Year: 2007
    ..administrative component: ..